An AI model for prostate MRI offered an 89 percent AUC for prostate cancer detection in external validation testing, according to a newly published international multicenter study.
|Articles|June 11, 2012
SNM Image of the Year: Bi-213-DOTATOC
Author(s)Diagnostic Imaging Staff
SNM’s 2012 Image of the Year shows the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of GEP-NETs that do not respond to beta therapy.
Advertisement
The Society of Nuclear Medicine’s 2012 Image of the Year shows the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that do not respond to beta therapy.
Researchers at the annual meeting this week selected this image from more than 2,000 studies.The annual selection demonstrates the most cutting-edge nuclear medicine or molecular imaging research, SNM said. “The images illustrating the effectiveness of Bi-213-DOTATOC for GEP-NETs show the remarkable results that can be achieved in a clinical setting,” said Peter Herscovitch, MD, chair of SNM’s Scientific Program Committee. “This opens up a new door for those patients whose GEP-NETs do not respond to more standard radiotherapy.”
GEP-NETs are rare, slow-growing tumors that are often resistant to standard chemotherapy. In this study, a Bi-213-DOTATOC was synthesized using a microwave-assisted labeling protocol. Twenty-one patients who had previously shown a resistance to treatment with Y-90 or Lu-177-DOTATOC were treated with escalating doses of the peptide receptor alpha-therapy - from 1-10 GBq up to 21 GBq. Researchers assessed response with Ga-68-DOTATOC PET/CT, contrast-enhanced sonography, MRI, digital subtraction angiography, and tumor markers. In addition, markers for hematologic, kidney and endocrine toxicity were monitored during and after treatment, according to the organization.
The labeling protocol for Bi-213-DOTATOC provided reliable doses of the treatment at a clinical level. Patients tolerated the increasing doses well, and there was no acute kidney, endocrine or hematologic toxicity. Researchers observed shrinkage of primary tumors as well as liver and bone metastases, according to SNM.
Alfred Morgenstern, PhD, project leader of the Alpha-Immunotherapy Project at the European Commission, Joint Research Centre, Institute for Transuranium Elements in Karlsruhe, Germany is the lead author of the study.
Responses to Bi-123 DOTANOC treatment observed in patients with tumors resistant to previous treatment with Y-90 or Lu-177-DOTATOC:
Advertisement
Related to this article
In the latest episode of her Breast Imaging in Focus series, Manisha Bahl, MD, MPH, FSBI, discusses new research comparing mammography-based AI models for breast cancer detection and short-term risk prediction.
In a recent episode of our Molecular Imaging in Focus series, Jack Andrews, MD, discussed pertinent findings from a recent intra-patient comparative study of PSMA PET agents in men with recurrent prostate cancer presented at the recent ASTRO conference.
The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
Expert Radiology is a **radiologist-run teleradiology practice with 10 years of experience**, hiring teleradiologists earning **$500–$900/hr with per-dictation pay**. Work from anywhere with true flexibility, **no shifts, no call, and no weekends**.
Our case mix is **predominantly outpatient and noncontrast**, with approximately **75% MRI**, plus X-ray and CT.
We cover **malpractice with tail**, handle all medical licensing, and ship you a **$10K reading station with six vertical 4K monitors**.
Minimum commitment is an **average of 400 cases per month**.
**Book a call with Brandi Escapule, Principal, Physician Services.**
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.
While the allure of partnership or a hierarchical promotion system for those who paid their dues once sounded promising, the current reality amid declining reimbursements, thinning practice margins and private equity acquisitions is going after the gig with the most optimal lifestyle and paycheck.
Catch up on the top radiology content of the past week.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Breast Imaging in Focus: Can AI Models for Breast Cancer Detection and Risk Prediction Be Used Interchangeably?
2
Molecular Imaging in Focus: Comparative PSMA PET Study Offers Insights for Men with Recurrent PCa and Low PSA Values
3
What a Large Prostate MRI Study Reveals About AI and Unassisted Radiologist Assessment
4
Can CT Bone Reading Software Enhance Detection of Metastatic Rib Lesions in Women with Breast Cancer?
5